ChemSpider 2D Image | EL9885000 | C17H26ClNO4

EL9885000

  • Molecular FormulaC17H26ClNO4
  • Average mass343.846 Da
  • Monoisotopic mass343.155029 Da
  • ChemSpider ID34111

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

(2,4,6-Trimethoxyphenyl) (3-Pyrrolidinopropyl) Ketone Hydrochloride
1-[4-Oxo-4-(2,4,6-trimethoxyphenyl)butyl]pyrrolidinium chloride [ACD/IUPAC Name]
1-[4-Oxo-4-(2,4,6-trimethoxyphenyl)butyl]pyrrolidiniumchlorid [German] [ACD/IUPAC Name]
1-Butanone, 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-, hydrochloride (1:1) [ACD/Index Name]
2',4',6'-Trimethoxy-4-(1-pyrrolidinyl)butyrophenone Hydrochloride
252-611-9 [EINECS]
35543-24-9 [RN]
4-(1-Pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone [ACD/IUPAC Name]
4-(1-Pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone hydrochloride
4-(Pyrrolidin-1-yl)-1-(2,4,6-trimethoxyphenyl)butan-1-one hydrochloride
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

3J944AFS8S [DBID]
A 48257 [DBID]
A-48257 [DBID]
LL 1656 [DBID]
MLS000028735 [DBID]
Prestwick_782 [DBID]
SMR000058803 [DBID]
UNII:3J944AFS8S [DBID]
UNII-3J944AFS8S [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Target Organs:

      Adrenergic Receptor antagonist TargetMol T0317

    • Bio Activity:

      ??-adrenergic receptor TargetMol T0317
      Buflomedil HCl is a vasodilator used to treat claudication or the symptoms of peripheral arterial disease. MedChem Express
      Buflomedil HCl is a vasodilator used to treat claudication or the symptoms of peripheral arterial disease.; Target: Others; Buflomedil is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. MedChem Express HY-B0484
      Buflomedil HCl is a vasodilator used to treat claudication or the symptoms of peripheral arterial disease.;Target: Buflomedil is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. In the EU, buflomedil, a vasoactive agent, was indicated for treatment of PAOD symptoms, specifically in patients with stage II PAOD who experience severe pain when walking even relatively short distances. Buflomedil is not currently approved by the US Food and Drug Administration for use in the United States. MedChem Express HY-B0484
      GPCR/G Protein TargetMol T0317
      Others MedChem Express HY-B0484

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

No predicted properties have been calculated for this compound.

Click to predict properties on the Chemicalize site


Advertisement